These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29973197)

  • 1. Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma.
    Li X; Zhao Z; Yi S; Ma L; Li M; Liu M; Zhang Y; Liu G
    J Transl Med; 2018 Jul; 16(1):183. PubMed ID: 29973197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ras signaling pathway mediates cetuximab resistance in nasopharyngeal carcinoma.
    Zuo Q; Shi M; Chen J; Liao W
    Biomed Pharmacother; 2011 Jun; 65(3):168-74. PubMed ID: 21602020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of silencing H-ras gene by RNA interference on cetuximab-sensitivity of cetuximab-resistant human nasopharyngeal carcinoma cells].
    Zuo Q; Luo RC
    Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):574-8. PubMed ID: 22325215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Value of [
    Gu B; Liu S; Sun Y; Zhang J; Zhang Y; Xu X; Yuan H; Wang M; Zhang Y; Yang Z
    Mol Imaging Biol; 2019 Jun; 21(3):538-548. PubMed ID: 30218389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VPS33B interacts with NESG1 to modulate EGFR/PI3K/AKT/c-Myc/P53/miR-133a-3p signaling and induce 5-fluorouracil sensitivity in nasopharyngeal carcinoma.
    Liang Z; Liu Z; Cheng C; Wang H; Deng X; Liu J; Liu C; Li Y; Fang W
    Cell Death Dis; 2019 Apr; 10(4):305. PubMed ID: 30944308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance.
    Zuo Q; Shi M; Li L; Chen J; Luo R
    Biomed Pharmacother; 2010 Oct; 64(8):550-8. PubMed ID: 20630698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between the insulin-like growth factor 1 receptor signaling pathway and the resistance of nasopharyngeal carcinoma to cetuximab].
    Zuo Q; Luo RC
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):575-9. PubMed ID: 21122407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
    Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
    Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling.
    Hu WJ; Liu J; Zhong LK; Wang J
    Biomed Pharmacother; 2018 Jun; 102():681-688. PubMed ID: 29604587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma.
    Mai J; Zhong ZY; Guo GF; Chen XX; Xiang YQ; Li X; Zhang HL; Chen YH; Xu XL; Wu RY; Yu Y; Li ZL; Peng XD; Huang Y; Zhou LH; Feng GK; Guo X; Deng R; Zhu XF
    Theranostics; 2019; 9(12):3541-3554. PubMed ID: 31281496
    [No Abstract]   [Full Text] [Related]  

  • 12. Loss of cytoplasmic KLF4 expression is correlated with the progression and poor prognosis of nasopharyngeal carcinoma.
    Liu Z; Yang H; Luo W; Jiang Q; Mai C; Chen Y; Zhen Y; Yu X; Long X; Fang W
    Histopathology; 2013 Sep; 63(3):362-70. PubMed ID: 23758499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation between ras gene and the resistance of nasopharyngeal carcinoma to cetuximab].
    Zuo Q; Luo RC
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1415-7. PubMed ID: 20584693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
    Prenen H; De Schutter J; Jacobs B; De Roock W; Biesmans B; Claes B; Lambrechts D; Van Cutsem E; Tejpar S
    Clin Cancer Res; 2009 May; 15(9):3184-8. PubMed ID: 19366826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
    Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
    Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
    Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
    J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
    Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
    Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
    O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
    Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.